NVCR - NovoCure Limited

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
44.98
+0.48 (+1.08%)
As of 12:30PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close44.50
Open44.62
Bid45.12 x 1200
Ask45.17 x 900
Day's Range44.25 - 45.38
52 Week Range19.06 - 53.70
Volume621,102
Avg. Volume829,579
Market Cap4.184B
Beta (3Y Monthly)2.84
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Tamarack Capital Management’s Return, AUM, and Holdings
    Insider Monkey5 days ago

    Tamarack Capital Management’s Return, AUM, and Holdings

    Tamarack Capital Management is a hedge fund that was founded by Mr. Justin John Ferayorni, its current Chief Investment Officer and Portfolio Manager. Before deciding to start his own firm, Mr. Ferayorni built up serious experience in investing, working as a Healthcare Analyst and Portfolio Manager, and later own as a Director of Research at […]

  • Stocks down in December for pharma firms in the Triangle
    American City Business Journals20 days ago

    Stocks down in December for pharma firms in the Triangle

    Pharmaceutical companies in the Triangle were far from exempt from a worldwide dive in stock prices, with some companies sliding more than 50 percent.

  • Is NovoCure a Buy?
    Motley Fool23 days ago

    Is NovoCure a Buy?

    Investors in the cancer-focused medical device company have enjoyed strong returns already. Is it too late to hop on board?

  • Simply Wall St.last month

    What Kind Of Shareholder Owns Most NovoCure Limited (NASDAQ:NVCR) Stock?

    Every investor in NovoCure Limited (NASDAQ:NVCR) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease Read More...

  • Is NovoCure Limited (NVCR) A Good Stock To Buy?
    Insider Monkeylast month

    Is NovoCure Limited (NVCR) A Good Stock To Buy?

    Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]

  • 3 Top Medical Device Stocks to Buy Now
    Motley Foollast month

    3 Top Medical Device Stocks to Buy Now

    Align Technology, NovoCure, and DexCom look poised for explosive growth.

  • Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today
    Market Realistlast month

    Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today

    Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10. That day, the stock price closed at $20.89, which is a ~63% fall from its 52-week high of $56.70 on December 21, 2017. The stock price fell from $48.68 at the close of the market on December 29, 2017, to $20.89 on December 10, 2018, reflecting a ~57% YTD (year-to-date) fall. Portola Pharmaceuticals hit a 52-week low of $18.18 on November 7.

  • 3 Top Healthcare Stocks to Buy in November
    Motley Fool2 months ago

    3 Top Healthcare Stocks to Buy in November

    An insurer, a medical device company, and a healthcare Goliath could all be smart additions to portfolios this month.

  • Simply Wall St.2 months ago

    NovoCure Limited (NASDAQ:NVCR): Is Breakeven Near?

    NovoCure Limited’s (NASDAQ:NVCR): NovoCure Limited engages in the development, manufacture, and commercialization of Tumor Treating Fields for the treatment of solid tumors. The US$2.9b market-cap company’s loss lessens since it Read More...

  • Here's Why NovoCure Fell 36.8% in October
    Motley Fool2 months ago

    Here's Why NovoCure Fell 36.8% in October

    The biopharma stock had more than doubled from the beginning of 2018 to the end of September. Why are investors suddenly pessimistic?

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of NVCR earnings conference call or presentation 25-Oct-18 12:00pm GMT

    Q3 2018 Novocure Ltd Earnings Call

  • Here's Why Novocure Is Tumbling Today
    Motley Fool3 months ago

    Here's Why Novocure Is Tumbling Today

    Shares plunged after the company reported mixed quarterly results. Here are the must-know details for investors.

  • NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates
    Zacks3 months ago

    NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates

    NovoCure (NVCR) delivered earnings and revenue surprises of 13.33% and -1.30%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Gauging Analysts’ Views for NovoCure Stock
    Market Realist3 months ago

    Gauging Analysts’ Views for NovoCure Stock

    Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.” The mean rating for NovoCure is 1.6 with a target price of $56.50. That implies an upside potential of 24.4% over its trading price of $45.42 on October 18.

  • NovoCure’s Operational Performance in Q3 2018: What to Expect
    Market Realist3 months ago

    NovoCure’s Operational Performance in Q3 2018: What to Expect

    NovoCure’s (NVCR) gross income is expected to rise 28.22% to $44.82 million in the third quarter of 2018. Its gross margin is expected to contract from 69.76% in the third quarter of fiscal 2017 to 68.7% in the third quarter of fiscal 2018. NovoCure’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 67.97% and 72.72%, respectively.

  • NovoCure: Its Top-Line Forecast for Q3 2018
    Market Realist3 months ago

    NovoCure: Its Top-Line Forecast for Q3 2018

    NovoCure (NVCR) is expected to report its third quarter of fiscal 2018 earnings on October 25. NovoCure’s clinical programs are evaluating the use of tumor-treating fields in various indications, including brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and liver cancer. Analysts expect NovoCure’s revenues to increase 30.47%, from $50.11 million in the third quarter of fiscal 2017 to $65.38 million in the third quarter of fiscal 2018.

  • NovoCure (NVCR) Q3 Earnings Preview: What to Look Out For
    Zacks3 months ago

    NovoCure (NVCR) Q3 Earnings Preview: What to Look Out For

    NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why Novocure Stock Jumped 16.3% in September
    Motley Fool3 months ago

    Why Novocure Stock Jumped 16.3% in September

    Shares of this medical device company that's aiming to revolutionize cancer treatment are up 123% in 2018.

  • 3 Medical Devices Stocks to Buy
    InvestorPlace3 months ago

    3 Medical Devices Stocks to Buy

    When you think of medical devices stocks, you don’t think of cloud-connected watches. You want to invest in more prosaic companies, large and small, which offer discrete devices for specific conditions, with Food and Drug Administration (FDA) approvals and positive clinical trials. The long-term prognosis for medical devices is good, but many companies need to deal with short-term problems to get there, so look for strength – financial strength or strength within a winning niche – when you shop for investments.

  • What Investors Should Know About NovoCure Limited’s (NASDAQ:NVCR) Financial Strength
    Simply Wall St.4 months ago

    What Investors Should Know About NovoCure Limited’s (NASDAQ:NVCR) Financial Strength

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as NovoCure Limited (NASDAQ:NVCR) with a market-capitalization of US$4.36b, rarely draw their attention. However, history shows that overlookedRead More...

  • 5 Medical Device Stocks With Impressive Staying Power
    InvestorPlace4 months ago

    5 Medical Device Stocks With Impressive Staying Power

    Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. All in all, the combination of the two factors makes the medical device stocks some of best plays in all of healthcare.

  • Why Novocure Gained 33% in August
    Motley Fool4 months ago

    Why Novocure Gained 33% in August

    Wall Street is excited about the growing potential for the company's cancer-fighting treatments.

  • NovoCure Stock Rose after Positive Results from Clinical Trial
    Market Realist4 months ago

    NovoCure Stock Rose after Positive Results from Clinical Trial

    On September 6, NovoCure (NVCR) stock rose 5.3% to reach $45.40 compared to the previous day’s close of $43.10. Also, on September 6, NovoCure hit its 52-week high of $46.73. Its closing price for the day represents ~182% growth from its 52-week low of $16.10 on October 13, 2017.

  • Stocks - Cloudera, Verint Systems, Novocure Soar in Pre-market; Lands' End Tumbles
    Investing.com4 months ago

    Stocks - Cloudera, Verint Systems, Novocure Soar in Pre-market; Lands' End Tumbles

    Investing.com - Stocks in focus in pre-market trade Thursday:

  • This brain cancer drug stock has been on a tear
    Yahoo Finance5 months ago

    This brain cancer drug stock has been on a tear

    This year, more than 14,000 people in the U.S. will be diagnosed with the same kind of brain cancer that killed Senator John McCain, glioblastoma multiforme, or GBM.